{"entity":{"id":"hedy-kindler","kind":"person","name":"Hedy L. Kindler","aka":[],"tldr":"Senior investigator of POLO and a leader in mesothelioma trials, including the ASCO guidelines for the disease.","summary":"Hedy Kindler was senior author of the POLO trial of olaparib in BRCA-mutant pancreatic cancer and chaired the ASCO mesothelioma guideline. She has led national trials of bevacizumab and other agents in pancreatic cancer and mesothelioma through CALGB and Alliance. She directs GI oncology and mesothelioma programmes at the University of Chicago.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kindler%20HL%5BAuthor%5D%20mesothelioma%20OR%20pancreatic"}],"tags":["pancreatic","mesothelioma","guidelines"],"related":[],"cancers":["pancreatic","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib"],"companies":[],"institutions":["uchicago-cancer"],"pathways":[],"terms":[],"trials":["polo"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine and Director of Gastrointestinal Oncology and Mesothelioma Programs, University of Chicago","institutionId":"uchicago-cancer","specialisms":["Pancreatic cancer","Mesothelioma","Targeted therapy","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kindler%20HL%5BAuthor%5D%20mesothelioma%20OR%20pancreatic"}],"papers":[{"title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer (POLO)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1903387"},{"title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","journal":"JCO","year":2018,"doi":"10.1200/JCO.2017.76.6394"}]},"route":"/people/hedy-kindler/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"institution":[{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","route":"/institutions/uchicago-cancer/"}],"trial":[{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"}],"paper":[{"id":"paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022","kind":"paper","name":"POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/"},{"id":"paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019","kind":"paper","name":"POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/"}]}}